In one study, topical dorzolamide given twice daily showed some improvement in fluorescein angiographic appearance in 2 of 5 patients compared with placebo, but visual acuity was not improved in any of the patients.233 Conversely, oral acetazolamide showed improvement in visual acuity in 3 of 5 patients and improvement in fluorescein angiographic appearance in all 5 patients. This suggests that topical dorzolamide may have some positive effect, but oral acetazolamide is superior in this particular application.

Carbonic anhydrase inhibitors are also used in cases of benign intracranial hypertension (pseudotumor cerebri)234 and in preventing and treating mountain (high-altitude) sickness.235 Acetazolamide has also been used in central retinal artery occlusion in the hopes of dilating the retinal vasculature and allowing the embolus or thrombus to move downstream.236

References

 1. Becker B: Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox,Am J Ophthalmol 37:13, 1954.

 2. Lütjen-Drecoll E, Lonnerholm G: Carbonic anhydrase distribution in the rabbit eye by light and electron microscopy, Invest OphthalmolVis Sci 21:782, 1981.

 3. Dobbs PC, Epstein DL,Anderson PJ: Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes, Invest OphthalmolVis Sci 18:867, 1979.

 4. Wistrand PJ, Garg LC: Evidence of a high activity C type of carbonic anhydrase in human ciliary processes, Invest OphthalmolVis Sci 18:802, 1979.

 5. Schwam H, et al: Identification and partial purification of a sodium dodecyl sulfate resistant carbonic anydrase activity from the rabbit ciliary process, Invest OphthalmolVis Sci 34(suppl):930, 1993.

 6. Sugrue MF, et al:A study of the in vitro inhibition of human carbonic anhydrase isoenzymes I, II, and IV, Invest OphthalmolVis Sci 34(suppl):1143, 1993.

 7. Jampel HD, et al: Expression of carbonic anhydrase isozyme III in the ciliary processes and lens, Invest OphthalmolVis Sci 38:539, 1997.

 8. Kim CY, et al: Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV, J Med Chem 45:888, 2002.

 9. Becker B, Constant MA: Experimental tonography: the effect of the carbonic anhydrase inhibitor acetazolamide on aqueous flow,Arch Ophthalmol

54:321, 1955.

10.Bloom JN, et al: Fluorophotometry and the rate of aqueous flow in man. I. Instrumentation and normal values,Arch Ophthalmol 94:435, 1976.

11.Linner E, Friedenwald JS:The appearance time of fluorescein as an index of aqueous flow,Am J Ophthalmol 44:225, 1957.

12.Holm O,Wiebert O:The effect of systemically given acetazolamide (Diamox) on the formation of aqueous humor in the human eye measured with a new photogrammetric method,Acta Ophthalmol (Copenh) 46:1243, 1968.

13.Constant MA, Falch J: Phosphate and protein concentrations of intraocular fluids. I. Effect of carbonic anhydrase inhibition in young and old rabbits, Invest OphthalmolVis Sci 2:332, 1963.

14.Becker B:The effects of acetazolamide on ascorbate acid turnover: an application of the theory of aqueous humor dynamics,Am J Ophthalmol 41:522, 1956.

15.KinseyVE, Reddy DVN, Skrentny BA: Intraocular transport of 14C-labelled urea and the influence of Diamox on its rate of accumulation in aqueous humors,Am J Ophthalmol 150:1130, 1960.

16.Becker B:The measurement of aqueous flow with iodide, Invest OphthalmolVis Sci 1:52, 1962.

17.Macri FJ, Dixon RL, Rall DP:Aqueous humor turnover rates in the cat. I. Effect of acetazolamide, Invest OphthalmolVis Sci 4:927, 1965.

18.Oppelt WW: Measurement of aqueous humor formation rates by posterior–anterior chamber perfusion with inulin: normal values and the effect of carbonic anhydrase inhibition, Invest OphthalmolVis Sci 6:76, 1967.

19.Friedenwald JS: Current studies on acetazolamide (Diamox) and aqueous humor flow,Am J Ophthalmol 40:139, 1955.

20.Maren TH, et al:The pharmacology of methazolamide in relation to the treatment of glaucoma, Invest OphthalmolVis Sci 16:730, 1977.

21.Berggren L: Direct observation of secretory pumping in vitro of the rabbit eye ciliary processes: influence of ion milieu and carbonic anhydrase inhibition, Invest OphthalmolVis Sci 3:266, 1964.

22.Krupin T, et al: Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency,Am J Ophthalmol 99:396, 1985.

23.Stone RA, et al: Low-dose methazolamide and intraocular pressure,Am J Ophthalmol 83:674, 1977.

24.Becker B:The mechanism of the fall in intraocular pressure induced by the carbonic anhydrase inhibitor Diamox,Am J Ophthalmol 39:177, 1955.

25.Friedman Z, Krupin T, Becker B: Ocular and systemic effects of acetazolamide in nephrectomized rabbits, Invest OphthalmolVis Sci 23:209, 1982.

26.Maren TH, et al:The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion, Exp Eye Res 36:457, 1983.

27.Stein A, et al:The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits,Am J Ophthalmol 95:222, 1983.

28.Buclin T, et al:Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects, Clin Pharmacol Ther 49:665, 1991.

29.Lewis RA, et al:Aminozolamide gel: a trial of a topical carbonic anhydrase inhibitor in ocular hypertension,Arch Ophthalmol 104:842, 1986.

30.Bron AM, et al: MK-927: a topically effective carbonic anhydrase inhibitor in patients,Arch Ophthalmol 107:1143, 1989.

31.Foss RH: Local application of Diamox: an experimental study of its effect on the intraocular pressure,Am J Ophthalmol 39:336, 1955.

32.Green HG, Leopold IH: Effects of locally administered Diamox,Am J Ophthalmol 40:137, 1955.

33.Wistrand PJ: Local action of the carbonic anhydrase inhibitor, acetazolamide, on the intraocular pressure in cats,Arch Pharmacol Toxicol 14:27, 1957.

34.Zimmerman TJ, et al:The effect of acetazolamide on the movements of anions into the posterior chamber of the dog eye, J Pharmacol Exp Ther 196:510, 1976.

35.Becker B:The effects of the carbonic anhydrase inhibitor, acetazolamide, on the composition of aqueous humor,Am J Ophthalmol 40:129, 1955.

36.Becker B: Carbonic anhydrase and the formation of aqueous humor: the Friedenwald Memorial Lecture, Am J Ophthalmol 47:342, 1959.

37.KinseyVE, Reddy DVN:Turnover of carbon dioxide in the aqueous humor and the effect thereon of acetazolamide,Arch Ophthalmol 62:78, 1959.

38.Maren TH:The rates of movement of Na , Cl, and

HCO3 from plasma to posterior chamber: effect of acetazolamide and relation to the treatment of glaucoma, Invest OphthalmolVis Sci 15:356, 1976.

39.Shahidullah M, et al: Effects of ion transport and channel-blocking drugs on aqueous humor

formation in isolated bovine eye, Invest Ophthalmol Vis Sci 44:1185, 2003.

40.To CH, et al: Model of ionic transport for bovine ciliary epithelium: effects of acetazolamide and HCO, Am J Physiol Cell Physiol 280:C1521, 2001.

41.Cotlier E: Bicarbonate ATP-ase in ciliary body and a theory of Diamox effect on aqueous humor formation, Int Ophthalmol 1:123, 1979.

42.Gonzales-Jimenez ER, Leopold IH: Chlorothiazide and ocular pressure,Arch Ophthalmol 60:70, 1958.

43.Henry MM, Lee PF: Clinical comparison of dichlorphenamide, chlorothiazide and sulocarbilate with acetazolamide in control of glaucoma,Am J Ophthalmol 47:199, 1959.

44.Gelatt KN, MacKay EO: Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs,Vet Ophthalmol 4:61, 2001.

45.Bietti G, et al:Acetazolamide, metabolic acidosis and intraocular pressure,Am J Ophthalmol 80:360, 1975.

46.Langham ME, Lee PM:Action of Diamox and ammonium chloride on the formation of aqueous humor, Br J Ophthalmol 41:65, 1957.

47.Krupin T, et al:Acidosis, alkalosis and aqueous humor dynamics in rabbits, Invest OphthalmolVis Sci 16:997, 1977.

48.Mehra KS: Relationship of pH of aqueous and blood with acetazolamide,Ann Ophthalmol 11:63, 1979.

49.Soser M, et al: New findings concerning changes in intraocular pressure and blood acidosis after peroral application of acetazolamide, Klin Monatsbl Augenheilkd 176:88, 1980.

50.Macri FJ, Cevario SJ: Blockade of the ocular effects of acetazolamide by phencyclidine, Exp Eye Res 24:121, 1977.

51.Bill A: Effects of acetazolamide and carotid occlusion on the ocular blood flow in unanesthetized rabbits, Invest OphthalmolVis Sci 13:954, 1974.

52.Lütjen-Drecoll E, Eichorn M, Barany EH: Carbonic anhydrase in epithelia and fenestrated juxtaepithelial capillaries of macaca fascicularis,Acta Physiol Scand 124:295, 1985.

53.Macri FJ:Acetazolamide and the venous pressure of the eye,Arch Ophthalmol 63:953, 1965.

54.Thomas RP, Riley MW:Acetazolamide and ocular tension: notes concerning the mechanism of action, Am J Ophthalmol 60:204, 1965.

55.Maren TH: Relations between structure and biologic activity of sulfonamides,Ann Rev Pharmacol Toxicol 16:309, 1976.

56.Maus TL, et al: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans,Arch Ophthalmol 115:45, 1997.

57.Grant WM,Trotter RR: Diamox (acetazolamide) in the treatment of glaucoma,Arch Ophthalmol 51:735, 1954.

58.LottiVJ, Schmitt CH, Gautheron PD:Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits, Graefes Arch Clin Exp Ophthalmol 222:13, 1984.

59.Friedman Z,Allen RC, Raph SM:Topical acetazolamide and methazolamide delivered by contact lenses,Arch Ophthalmol 103:963, 1985.

60.Bar-Ilan A:The effects of separate and combined topical treatment with timolol maleate and trifluoromethazolamide on the intraocular pressure in normal rabbits, Curr Eye Res 3:1305, 1984.

61.Lippa EA, et al: Local tolerance and activity of MK927, a novel topical carbonic anhydrase inhibitor, Arch Ophthalmol 106:1694, 1988.

62.Wang RF, et al: MK-507 (L-671, 152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys,Arch Ophthalmol 109:1297, 1991.

63.Lewis RA, et al: Ethoxzolamide analogue gel: a topical carbonic anhydrase inhibitor,Arch Ophthalmol 102:1821, 1984.

64.Eller MG, Schoenwald RD: Determination of ethoxzolamide in the iris/ciliary body of the rabbit eye by high-performance liquid chromatography: comparison of tissue levels following intravenous and topical administrations, J Pharm Sci 73:1261, 1984.

65.Kalina PH, et al: 6-Amino-2-benzothiazole- sulfonamide: the effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye, Ophthalmology 95:772, 1988.

66.Higginbotham EJ, et al: MK-927: a topical carbonic anhydrase inhibitor. Dose response and duration of action,Arch Ophthalmol 108:65, 1990.

67.Bron A, et al: Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors

sezolamide and MK-927,Arch Ophthalmol 109:50, 1991.

68.Wang RF, et al:The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671, 152 in glaucomatous monkeys,Arch Ophthalmol 108:511, 1990.

69.Lippa EA, et al: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor,Arch Ophthalmol 110:495, 1992.

70.Wilkerson M, et al: Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor,Arch Ophthalmol 111:1343, 1993.

71.Gross RL, Oram O: Update on carbonic anhydrase inhibitors, Ophthalmol Clin North Am 10:327, 1997.

72.Brubaker RF, et al: Comparison of the efficacy of betaxolol–brinzolamide and timolol–dorzolamide as suppressors of aqueous humor flow in human subjects, Ophthalmology 107:283, 2000.

73.YamazakiY, Miyamoto S, Sawa M: Effect of MK-507 on aqueous humor dynamics in normal human eyes, Jpn J Ophthalmol 38:92, 1994.

74.Martens-Lobenhoffer J, Banditt P: Clinical pharmaco­ kinetics of dorzolamide, Clin Pharmacokinet 41:197, 2002.

75.Maren TH, et al: Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor, J Ocul Pharmacol Ther 13:23, 1997.

76.Araie M, et al:The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents, J Ocul Pharmacol Ther 19:517, 2003.

77.Sugrue MF, Funk H, Klotzbuecher C: Comparison of the topical carbonic anhydrase inhibitor L-671, 152 and timolol in glaucoma monkeys, Invest OphthalmolVis Sci 31(suppl):232, 1990.

78.Strahlman E,Tipping R,Vogel R:A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol: International Dorzolamide Study Group,Arch Ophthalmol 113:1009, 1995.

79.Strahlman ER, et al:The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure: the Dorzolamide Additivity Study Group, Ophthalmology 103:1283, 1996.

80.Portellos M, Buckley EG, Freedman SF:Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma, J AAPOS 2:43, 1998.

81.Nesher R,Ticho U: Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects, Isr Med Assoc J 5:260, 2003.

82.Whitson JT, et al: Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension, J Glaucoma 13:168, 2004.

 83. Adamsons IA, et al:Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group,

J Glaucoma 7:395, 1998.

 84. Ott EZ, et al:A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years,Arch Ophthalmol 123:1177, 2005.

 85. Maris PJ Jr, Mandal AK, Netland PA: Medical therapy of pediatric glaucoma and glaucoma in pregnancy, Ophthalmol Clin North Am 18:461, 2005. vii.

 86. Hartenbaum D:The efficacy of dorzolamide,

a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension, Clin Ther 18:460, 1996.

 87. Wang RF, et al: Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes, J Glaucoma 9:458, 2000.

 88. Wayman LL, et al:Additive effect of dorzolamide on aqueous humor flow in patients receiving longterm treatment with timolol,Arch Ophthalmol 116:1438, 1998.

 89. Centofanti M, et al: Comparative acute effects

of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma, Graefes Arch Clin Exp Ophthalmol 238:302, 2000.

 90. Le HH, et al:The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications, J Ocul Pharmacol Ther 15:305, 1999.

 91. O’Connor DJ, Martone JF, Mead A:Additive intraocular pressure lowering effect of various medications with latanoprost,Am J Ophthalmol 133:836, 2002.

 92. Ozturk F, et al: Comparison of the efficacy

and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma, J Ocul Pharmacol Ther 21:68, 2005.

 93. Maruyama K, Shirato S:Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial, J Glaucoma 15:341, 2006.

 94. Strohmaier K, Snyder E,Adamsons I: Long-

term safety of Cosopt, a fixed combination of dorzolamide and timolol, Invest OphthalmolVis Sci 37(suppl):1102, 1996.

 95. Clineschmidt CM, et al:A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide–timolol combination to monotherapy with timolol or dorzolamide, Ophthalmology 106(12 suppl):17, 1999.

 96. Boyle JE, et al:A randomized trial comparing the dorzolamide–timolol combination given twice daily to monotherapy with timolol and dorzolamide, Ophthalmology 106(12 suppl):10, 1999.

 97. Choudhri S,Wand M, Shields MB:A comparison

of dorzolamide–timolol combination versus the concomitant drugs,Am J Ophthalmol 130:832, 2000.

 98. Coleman AL, et al:A 3-month randomized controlled trial of bimatoprost (LUNIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension, Ophthalmology 110:2362, 2003.

 99. Januleviciene I, et al:A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma

patients,Acta Ophthalmol Scand 82:730, 2004.

100.Fechtner RD, et al: Efficacy of the dorzolamide/ timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies, J Ocul Pharmacol Ther 21:242, 2005.

101.Lafuma A, Berdeaux G: Costs and persistence of carbonic anhydrase inhibitor versus alpha2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UKGPRD database, Curr Med Res Opin Apr:14, 2008. (Epub ahead of print.).

102.Dean T, et al: Brinzolamide (AL4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynamolgus monkey, Invest OphthalmolVis Sci 38(suppl):813, 1997.

103.Stewart R: Brinzolamide Comfort Study Group: the ocular comfort of tid-dosed brinzolamide 1.0% compared to tid-dosed dorzolamide 2.0% in patients with primary open angle glaucoma or ocular hypertension, Invest OphthalmolVis Sci 38(suppl):559, 1997.

104.Camras CB: Brinzolamide Primary Therapy Study Group:A triple-masked, primary therapy study of the efficacy and safety of bidand tiddosed brinzolamide 1% compared to tid-dosed dorzolamide 2% and bid-dosed timolol 0.5% (letter), Invest OphthalmolVis Sci 38:S560, 1997.

105.Silver LH: Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group,Am J Ophthalmol 126:400, 1998.

106.Sall K:The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group, Surv Ophthalmol 44(suppl 2):S155, 2000.

107.Nakamoto K,Yasuda N: Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma, J Glaucoma 16:352, 2007.

108.Shin DH:The Brinzolamide Adjunctive Therapy Study Group:A triple-masked, placebo-controlled adjunctive therapy study of the efficacy and safety of the tid-dosed Brinzolamide 1.0% compared

to tid-dosed placebo when used adjunctively to timolol 0.5%, Invest OphthalmolVis Sci 38:S559, 1997.

109.Michaud JE, Friren B: International Brinzolamide Adjunctive Study Group: Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension,Am J Ophthalmol 132:235, 2001.

110.Shoji N, et al: Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled,

open-label study, Curr Med Res Opin 21:503, 2005.

111.Tsukamoto H, et al:The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma, J Ocul Pharmacol Ther 21:170, 2005.

112.Tsukamoto H, et al:The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide,

J Ocul Pharmacol Ther 21:395, 2005.

113.Garner LL, Carl EF, Ferwerda JR:Advantages of sustained-release therapy with acetazolamide in glaucoma,Am J Ophthalmol 55:323, 1963.

114.Lichter PR: Reducing side effects of carbonic anhydrase inhibitors, Ophthalmology 88:266, 1981.

115.Lichter PR: Intraocular pressure effects of carbonic anhydrase inhibitors in primary open-angle glaucoma,Am J Ophthalmol 107:11, 1989.

116.Wistrand PJ, Rawls JA, Maren TH: Sulfonamide carbonic anhydrase inhibitors and intraocular pressure in rabbits,Acta Pharmacol Toxicol 17:377, 1960.

117.Chapron DJ, et al: Influence of advanced age on the distribution of acetazolamide, Br J Clin Pharmacol 19:363, 1985.

118.Maren TH: Chemistry of the renal reabsorption of bicarbonate, Can J Physiol Pharmacol 52:1041, 1974.

119.Dahlen K, et al:A repeated dose-response study of methazolamide in glaucoma,Arch Ophthalmol 96:2214, 1978.

120.Conroy CW, Schwann H, Maren TH:The nonenzymatic displacement of the sulfamoyl group

from different classes of aromatic compounds by glutathione and cysteine, Drug Metab Dispos 12:614, 1984.

121.Ellis PP: Urinary calculi with methazolamide therapy, Doc Ophthalmol 34:137, 1973.

122.Shields MB, Simmons RJ: Urinary calculus during methazolamide therapy,Am J Ophthalmol 81:622, 1976.

123.Holder L, Hayes S: Diffusion of sulfonamides in aqueous buffers and into red cells, Mol Pharmacol 1:266, 1965.

124.Beyer KH, Baer JE: Physiological basis for the action of newer diuretic agents, Pharmacol Rev 13:517, 1961.

125.Lichter PR, et al: Patient tolerance to carbonic anhydrase inhibitors,Am J Ophthalmol 85:495, 1978.

126.Silver LH: Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group, Surv Ophthalmol 44(suppl 2):S141, 2000.

127.Stewart WC, Stewart JA, Leech JN:Acute and chronic ocular symptoms of dorzolamide

2% compared with placebo, J Glaucoma 12:151,

2003.

128.Aalto-Korte K: Contact allergy to dorzolamide eyedrops, Contact Derm 39:206, 2006.

129.Kalavala M, Statham BN:Allergic contact dermatitis from timolol and dorzolamide eye drops, Contact Derm 54:345, 2006.

130.Hong S, et al: Effects of topical antiglaucoma application on conjunctival impression cytology specimens,Am J Ophthalmol 142:185, 2006.

131.Fineman MS, Katz LJ,Wilson RP:Topical dorzolamide-induced hypotony and ciliochoroidal detachment in patients with previous filtration surgery,Arch Ophthalmol 114:1031, 1996.

132.Callahan C,Ayyala RS: Hypotony and choroidal effusion induced by topical timolol and dorzolamide in patients with previous glaucoma drainage device implantation, Ophthalmic Surg Lasers Imaging 34:467, 2003.

133.Goldberg S, et al: Dorzolamide-induced choroidal detachment in a surgically untreated eye,Am J Ophthalmol 138:285, 2004.

134.Tsai JC, Chang HW: Refractive change after dorzolamide use in patients with primary openangle glaucoma and ocular hypertension, J Ocul Pharmacol Ther 17:499, 2001.

135.Kaminski S, et al: Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility,Acta Ophthalmol Scand 76:78, 1998.

136.Serle JB, et al: Six week safety study of 2% MK-927 administered twice daily to ocular hypertensive volunteers, J Ocul Pharmacol 8:1, 1992.

137.Lass JH, et al:A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group,Arch Ophthalmol 116:1003, 1998.

138.Baratz KH: Effects of glaucoma medications on corneal endothelium, keratocytes, and

subbasal nerves among participants in the ocular hypertension treatment study, Cornea 25:1046, 2006.

139.Giasson CJ, et al: Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension,Am J Ophthalmol 129:144, 2000.

140.Inoue K, et al: Influence of dorzolamide on corneal endothelium, Jpn J Ophthalmol 47:129, 2003.

141.Talluto DM,Wyse TB, Krupin T:Topical carbonic anhydrase inhibitors, Curr Opin Ophthalmol 8:2, 1997.

142.Konowal A, et al: Irreversible corneal decompensation in patients treated with topical dorzolamide,Am J Ophthalmol 127:403, 1999.

143.Trusopt (Merck) package insert.

144.Martin XD, Danese M: Dorzolamide-induced immune thrombocytopenia: a case report and literature, J Glaucoma 10:133, 2001.

145.Spivak D, Orion E, Brenner S: Bullous pemphigoid possibly triggered and exacerbated by ophthalmic preparations, Int J Dermatol 39:554, 2000.

146.Carlsen J, et al: Nephrolithiasis with dorzolamide, Arch Ophthalmol 117:1087, 1999.

147.MunshiV,Ahluwalia H: Erythema multiforme after use of topical dorzolamide, J Ocul Pharmacol Ther 24:91, 2008.

148.thoe Schwartzenberg GW,Trope GE:Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt), Can J Ophthalmol 34:93, 1999.

149.Wallace TR, et al: Deceased libido: a side effect of carbonic anhydrase inhibitor,Ann Ophthalmol 11:1563, 1979.

150.Glushien AS, Fisher ER: Renal lesions of sulfonamide type after treatment with

acetazolamide (Diamox), JAMA 160:204, 1956.

151.Birzis L, Carter CH, Maren TH: Effect of acetazolamide on CSF pressure and eletrolytes in hydrocephalus, Neurology 8:522, 1958.

152.Carmignani M, et al:Adverse interaction between acetazolamide and anticholinesterase drugs at the normal and myasthenic neuromuscular junction level, Int J Clin Pharmacol Ther 22:140, 1984.

153.Mallette LE:Anticonvulsants, acetazolamide and osteomalacia, N Engl J Med 292:668, 1975.

154.Krivoy N, et al: Methazolamide-induced hepatitis and pure RBC aplasia,Arch Intern Med 141:1229, 1981.

155.Aminlari A: Falling scalp hairs: a side effect of the carbonic anhydrase inhibitor, acetazolamide, Glaucoma 6:41, 1984.

156.Weiss IS: Hirsutism after chronic administration of acetazolamide,Am J Ophthalmol 78:327, 1974.

157.Shrader CE,Thomas JV, Simmons RJ: Relationship of patient age and tolerance to carbonic anhydrase inhibitors,Am J Ophthalmol 96:730, 1983.

158.Leopold IH, Eisenberg IJ,Yasuma J: Experience with Diamox in glaucoma,Am J Ophthalmol 39:885, 1955.

159.Block ER, Rostand RA: Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger?, Surv Ophthalmol 23:169, 1978.

160.Anderson CJ, Kaufman PL, Sturm RJ:Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin,Am J Ophthalmol 86:516, 1978.

161.Sweeney KR, et al:Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation, Clin Pharmacol Ther 40:518, 1986.

162.Galin MA, Baras I, Zweifach P: : Diamox-induced myopia,Am J Ophthalmol 54:237, 1962.

163.Beasley FJ:Transient myopia and related edema during ethoxzolamide (Cardase) therapy,Arch Ophthalmol 68:490, 1962.

164.Epstein DL, Grant WM: Carbonic anhydrase inhibitor side effects: serum chemical analysis,Arch Ophthalmol 95:1378, 1977.

165.Alward PD,Wilensky JT: Determination of acetazolamide compliance in patients with glaucoma,Arch Ophthalmol 99:1973, 1981.

166.Arrigg CA, et al:The influence of supplemental sodium acetate on carbonic anhydrase inhibitorinduced side effects,Arch Ophthalmol 99:1969, 1981.

167.Becker B, Middleton WH: Long-term acetazolamide (Diamox) administration in therapy of glaucomas,Arch Ophthalmol 54:187, 1955.

168.Draeger J, Gruttner R,Theilmann W:Avoidance of side-reactions and loss of drug efficacy during long-term administration of carbonic anhydrase inhibitors by concomitant supplemental electrolyte administration, Br J Ophthalmol 47:457, 1963.

169.Goldberg MF:The diagnosis and treatment of secondary glaucoma after hyphema in sickle cell patients,Am J Ophthalmol 87:43, 1979.

170.Spaeth GL: Potassium, acetazolamide, and intraocular pressure,Arch Ophthalmol 78:578, 1967.

171.Wisch N, et al:Aplastic anemia resulting from the usbonic anhydrase inhibitors,Am J Ophthalmol 75:130, 1973.

172.Gangitano JL, Foster SH, Contro RM: Nonfatal methazolamide-induced aplastic anemia,Am J Ophthalmol 86:138, 1978.

173.Fraunfelder FT, et al: Hematologic reactions to carbonic anhydrase inhibitors,Am J Ophthalmol 100:79, 1985.

174.Fraunfelder FT, Bagby GC: Possible hematologic reactions associated with carbonic anhydrase inhibitors, JAMA 261:2257, 1989.

175.Johnson T, Kass MA: Hematologic reaction to carbonic anhydrase inhibitors,Am J Ophthalmol 101:128, 1986.

176.Mogyk LG, Cyrlin MN: Blood dyscrasias and carbonic anhydrase inhibitors, Ophthalmology 95:768, 1988.

177.Gordon EE, Sheps SG: Effect of acetazolamide on citrate excretion and formation of renal calculi: report of a case and study of five normal subjects, N Engl J Med 256:1215, 1957.

178.Shah A, Constant MA, Becker B: Urinary excretion of citrate in humans following administration of acetazolamide (Diamox),Arch Ophthalmol 59:536, 1958.

179.Rubinstein MA, Bucy JG:Acetazolamide-induced renal calculi, J Urol 114:610, 1975.

180.Constant MA, Becker B:The effect of carbonic anhydrase inhibitors on urinary excretion of citrate by humans,Am J Ophthalmol 49:929, 1960.

181.Simpson DP: Effect of acetazolamide on citrate excretion in the dog,Am J Physiol 206:883, 1964.

182.Kass MA, et al:Acetazolamide and urolithiasis, Ophthalmology 88:261, 1981.

183.Takemoto M: Prophylaxis for acetazolamide induced urolithiasis: clinical study, Jpn J Urol 69:963, 1978.

184.Flach AJ, Smith RE, Fraunfelder FT: StevensJohnson syndrome associated with methazolamide treatment reported in two Japanese-American women, Ophthalmology 102:1677, 1995.

185.Worsham GF, Beckman EH, Mitchell EH: Sacrococcygeal teratoma in a neonate, JAMA 240:251, 1978.

186.Layton WM, Hallesy DM: Deformity of forelimb in rats: association with high doses of acetazolamide, Science 149:306, 1965.

187.Maren TH: Forelimb deformity in rats: association with acetazolamide, Science 150:79, 1965.

188.Wilson JG, et al:Teratogenic action of carbonic anhydrase inhibitors in the rat,Teratology 1:151, 1968.

189.Soderman P, Hartvig P, Fagerlund C:Acetazolamide excretion into human breast milk, Br J Clin Pharmacol 17:599, 1984.

190.Pierce WM Jr, et al: Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women, J Bone Miner Res 6:347, 1991.

191.Vorstrup S, Henriksen L, Paulson OB: Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen, J Clin Invest 74:1634, 1984.

192.Piepgras A, et al:A simple test to assess cerebrovascular reserve capacity using transcranial Doppler sonography and acetazolamide, Stroke 21:1306, 1990.

193.Mancini M, et al:Transcranial Doppler evaluation of cerebrovascular reactivity to acetazolamide in normal subjects,Artery 20:231, 1993.

194.Taki K, et al: Cascade of acetazolamide-induced vasodilatation, Res Commun Mol Pathol Pharmacol 103:240, 1999.

195.Puscas I, et al: Carbonic anhydrase I inhibition by nitric oxide: implications for mediation of the

hypercapnia-induced vasodilator response, Clin Exp Pharmacol Physiol 27:95, 2000.

196.Pickkers P, et al: In vivo evidence for K(Ca) channel opening properties of acetazolamide in the human vasculature, Br J Pharmacol 132:443, 2001.

197.Rassam SM, PatelV, Kohner EM:The effect of acetazolamide on the retinal circulation, Eye 7:697, 1993.

198.Dallinger S, et al: Effects of acetazolamide on choroidal blood flow, Stroke 29:997, 1998.

199.DeSantis L: Preclinical overview of brinzolamide, Surv Ophthalmol 44(suppl 2):S119, 2000.

200.Schmidt KG, von Ruckmann A, Pillunat LE:Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma, Br J Ophthalmol 82:758, 1998.

201.Nagel E,Vilser W, Lanzl I: Dorzolamide influences the autoregulation of major retinal vessels caused by artificial intraocular pressure elevation in patients with POAG: a clinical study, Curr Eye Res 30:129, 2005.

202.Pillunat LE, et al: Effect of topical dorzolamide on optic nerve head blood flow, Graefes Arch Clin Exp Ophthalmol 237:495, 1999.

203.Faingold D, et al:Assessment of retinal hemodynamics with the Canon laser blood flowmeter after a single dose of 2% dorzolamide hydrochloride eyedrops, Can J Ophthalmol 39:506, 2004.

204.Harris A, et al: Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma, J Ocul Pharmacol Ther 15:189, 1999.

205.Harris A, et al: Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma,Am J Ophthalmol 132:490, 2001.

206.Martinez A, et al: Dorzolamide effect on ocular blood flow, Invest OphthalmolVis Sci 40:1270, 1999.

207.Fuchsjager-Mayrl G, et al: Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension, Br J Ophthalmol 89:1293, 2005.

208.Pillunat LE: Effect of topical dorzolamide on optic nerve head blood flow, Graefes Arch Clin Exp Ophthalmol 237:495, 1999.

209.Schmidt KG, von Ruckmann A, Pillunat LE:Topical carbonic anhydrase inhibition increases ocular pulse amplitude in high tension primary open angle glaucoma, Br J Ophthalmol 82:758, 1998.

210.Bergstrand IC, Heijl A, Harris A: Dorzolamide and ocular blood flow in previously untreated glaucoma patients: a controlled double-masked study,Acta Ophthalmol Scand 80:176, 2002.

211.Arend O, et al: Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly

diagnosed open-angle glaucoma patients,Acta Ophthalmol Scand 81:474, 2003.

212.Simsek T, et al: Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma, J Ocul Pharmacol Ther 22:79, 2006.

213.Iester M: Retinal peripapillary blood flow before and after topical brinzolamide, Ophthalmologica 218:390, 2004.

214.SarupV, et al: Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats, J Ocul Pharmacol Ther 21:454, 2005.

215.Berson FG, et al:Acetazolamide dosage forms in the treatment of glaucoma,Arch Ophthalmol 98:1051, 1980.

216.Nordstrom BL, et al: Persistence and adherence with topical glaucoma therapy,Am J Ophthalmol 140:598, 2005.

217.Toris CB, et al: Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide, J Glaucoma 13:210, 2004.

218.Rosenberg LF, et al: Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation, Ophthalmology 105:88, 1998.

219.Sabri K, Levin AV:The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma, J AAPOS 10:464, 2006.

220.Leopold IH, Carmichael PL: Prolonged administration of Diamox in glaucoma,Trans Am Acad Ophthalmol Otolaryngol 60:210, 1956.

221.Ellis PP, et al: Effectiveness of generic acetazolamide, Arch Ophthalmol 100:1920, 1982.

222.Berson FG, Epstein DL: Separate and combined effects of timolol maleate and acetazolamide in open-angle glaucoma,Am J Ophthalmol 92:788, 1981.

223.Smith JP, et al: Betaxolol and acetazolamide: combined ocular hypotensive effect,Arch Ophthalmol 102:1794, 1984.

224.Kass MA, et al:Timolol and acetazolamide: a study of concurrent administration, Arch Ophthalmol 100:941, 1982.

225.Konstas AG, et al:Twenty-four hour control of intraocular pressure with dorzolamide and timolol

maleate in exfoliation and primary open-angle glaucoma, Eye 14:73, 2000.

226.Franks W: Brinzolamide Study Group: Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension, Curr Med Res Opin 22:1643, 2006.

227.Sabri K, Levin AV:The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma, J AAPOS 10:464, 2006.

228.Friedland BR, Mallonee J,Anderson DR: Shortterm dose response characteristics of acetazolamide in man,Arch Ophthalmol 95:1809, 1977.

229.Berson FG, et al:Acetazolamide dosage forms in the treatment of glaucoma,Arch Ophthalmol 98:1051, 1980.

230.Marmor MF,Abdul-Rahim AS, Cohen DS: The effect of metabolic inhibitors on retinal adhesion and subretinal fluid reabsorption, Invest OphthalmolVis Sci 19:893, 1980.

231.Cox SN, Hay E, Bird AC:Treatment of chronic macular edema with acetazolamide,Arch Ophthalmol 106:1190, 1988.

232.Fishman GA, et al:Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa,Arch Ophthalmol 107:1445, 1989.

233.Grover S, et al: Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa, Retina 17:222, 1977.

234.Liu GT, Glaser JS, Schatz NJ: High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri,Am J Ophthalmol 118:88, 1994.

235.Clarke C: High altitude cerebral oedema, Int J Sports Med 9:170, 1988.

236.Rumelt S, DorenboimY, Rehany U:Aggressive systematic treatment for central retinal artery occlusion,Am J Ophthalmol 128:733, 1999.